Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Standard BioTools Inc. (LAB : NSDQ)

• Company Description    Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 389

• Price / Volume Information    Yesterday's Closing Price: $1.03 Daily Weekly Monthly 20 Day Moving Average: 2,045,489 shares Shares Outstanding: 390.37 (millions) Market Capitalization: $402.08 (millions) Beta: 1.32 52 Week High: $1.72 52 Week Low: $0.87 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.23% 9.60% 12 Week -11.97% -18.62% Year To Date -19.53% -25.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 50 Milk Street 10th Floor - Boston,MA 02109 USA ph: 650-266-6000 fax: 650-871-7152 investors@standardbio.com http://www.standardbio.com

• General Corporate Information    Officers Michael Egholm - President and Chief Executive Officer Tom Carey - Chairman of the Board Alex Kim - Chief Financial Officer Fenel M. Eloi - Director Eli Casdin - Director Peer Information Standard BioTools Inc. (HLIS) Standard BioTools Inc. (AZTA) Standard BioTools Inc. (APYI) Standard BioTools Inc. (RNVA) Standard BioTools Inc. (HMSY) Standard BioTools Inc. (LRSI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: 34385P108 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 390.37 Most Recent Split Date: (:1) Beta: 1.32 Market Capitalization: $402.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.10 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.72 Price/Cash Flow: - Price / Sales: 3.78 EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: -160.00% Sales Growth vs. Year Ago Period: -48.17% vs. Previous Quarter: -11.13% ROE 03/31/26 - -8.18 12/31/25 - -11.21 09/30/25 - -20.89 ROA 03/31/26 - -6.43 12/31/25 - -8.51 09/30/25 - -15.98 Current Ratio 03/31/26 - 12.36 12/31/25 - 4.19 09/30/25 - 4.38 Quick Ratio 03/31/26 - 11.92 12/31/25 - 4.01 09/30/25 - 4.14 Operating Margin 03/31/26 - -34.76 12/31/25 - -37.85 09/30/25 - -61.33 Net Margin 03/31/26 - 73.46 12/31/25 - -59.39 09/30/25 - -86.06 Pre-Tax Margin 03/31/26 - -82.50 12/31/25 - -113.33 09/30/25 - -57.60 Book Value 03/31/26 - 1.44 12/31/25 - 1.10 09/30/25 - 1.05 Inventory Turnover 03/31/26 - 1.97 12/31/25 - 1.53 09/30/25 - 1.18 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.05 12/31/25 - 0.07 09/30/25 - 0.07

Powered by Zacks Investment Research ©